Ovid Therapeutics Inc OVID:NASDAQ

Last Price$2.20Cboe Closing Price as of 3:59PM ET 8/10/22
Cboe Real-Time Quotes
Today's Change+0.02(0.92%)
Bid (Size)$1.78 (100)
Ask (Size)$2.77 (100)
Day Low / High$2.20 - 2.23
Volume31.6 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/10/2022

 

Ovid Therapeutics Inc ( NASDAQ )

Price: $2.20
Change: +0.02 (0.92%)
Volume: 31.6 K
3:59PM ET 8/10/2022
 
 

PDS Biotechnology Corp ( NASDAQ )

Price: $5.64
Change: +0.32 (6.02%)
Volume: 316.6 K
4:00PM ET 8/10/2022
 
 

scPharmaceuticals Inc ( NASDAQ )

Price: $5.55
Change: +0.05 (0.91%)
Volume: 85.7 K
4:00PM ET 8/10/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Trevi Therapeutics Inc ( NASDAQ )

Price: $4.26
Change: +0.17 (4.16%)
Volume: 367.8 K
3:59PM ET 8/10/2022
 

Read more news Recent News

--Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating
9:31AM ET 5/20/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $1.4M
8:09AM ET 5/10/2022 MT Newswires

...

Ovid Therapeutics, Healx Reach Agreement on Fragile X Syndrome Treatment Candidate Gaboxadol
8:51AM ET 2/08/2022 MT Newswires

Ovid Therapeutics (OVID) said Tuesday that entered into a strategic partnership with Healx, which secured from the biopharmaceutical company an exclusive...

Ovid Therapeutics Obtains Exclusive License to AstraZeneca's Epilepsy Drug Candidate
7:06AM ET 1/03/2022 MT Newswires

Ovid Therapeutics (OVID) said Monday it has obtained an exclusive license to AstraZeneca's (AZN) experimental epilepsy drug OV350 and other early-stage...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionOvid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. View company web site for more details
Address1460 Broadway
New York, New York 10036
Phone+1.646.661.7661
Number of Employees55
Recent SEC Filing08/09/20228-K
Chairman, President & Chief Executive OfficerJeremy Max Levin
Chief Operating OfficerJason Tardio
Chief Financial & Business OfficerJeffrey A. Rona
Head-Research & DevelopmentClaude Nicaise

Company Highlights

Price Open$2.20
Previous Close$2.18
52 Week Range$1.65 - 4.20
Market Capitalization$154.9 M
Shares Outstanding70.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.00
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-4,734.49%
Return on Equity-36.57%

Analyst Ratings as of 03/17/2022

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset